Accelerated Approval Labeling Caveat Draws Industry Ire
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA draft proposal could lead providers, patients and insurers to mistakenly believe a drug cleared under the expedited pathway does not meet the same standards as other drugs, PhRMA and BIO say.